We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

109 hedge funds and large institutions have $144M invested in Aclaris Therapeutics in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 27 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 12

69% more call options, than puts

Call options by funds: $83K | Put options by funds: $49K

44% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 27

11% more funds holding

Funds holding: 98 → 109 (+11)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

34% less capital invested

Capital invested by funds: $217M → $144M (-$73.3M)

36.61% less ownership

Funds ownership: 122.51% → 85.9% (-37%)

Holders
109
Holders Change
+11
Holders Change %
+11.22%
% of All Funds
1.46%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
23
Increased
39
Reduced
27
Closed
12
Calls
$83K
Puts
$49K
Net Calls
+$34K
Net Calls Change
-$444K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$4.64M
2
DC
Decheng Capital
California
+$3.79M
3
BG
Bollard Group
Massachusetts
+$3.04M
4
Morgan Stanley
Morgan Stanley
New York
+$2.87M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.78M

Top Sellers

1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$6.99M
2
SB
Samsara BioCapital
California
-$5.91M
3
RSCM
Rock Springs Capital Management
Maryland
-$2.47M
4
PLC
Peapod Lane Capital
New York
-$1M
5
EAM
Exome Asset Management
New York
-$966K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
51
T. Rowe Price Associates
Maryland
$189K – – –
Barclays
52
Barclays
United Kingdom
$182K +$221K +103,800 +683%
CSS
53
Cubist Systematic Strategies
Connecticut
$132K -$362K -169,744 -66%
AA
54
ALPS Advisors
Colorado
$121K +$44.8K +21,022 +36%
UBS Group
55
UBS Group
Switzerland
$113K +$9.66K +4,529 +7%
Balyasny Asset Management
56
Balyasny Asset Management
Illinois
$108K +$150K +70,502 New
SG Americas Securities
57
SG Americas Securities
New York
$104K +$145K +67,933 New
JG
58
Jain Global
New York
$100K +$87.9K +41,212 +168%
ECM
59
ExodusPoint Capital Management
New York
$92K +$105K +49,228 +463%
Invesco
60
Invesco
Georgia
$87.3K +$97.8K +45,864 +409%
BFM
61
Boothbay Fund Management
New York
$81.8K -$126K -59,006 -52%
QC
62
Quantessence Capital
New York
$79K +$110K +51,664 New
LP
63
LMR Partners
United Kingdom
$74K +$103K +48,360 New
SOW
64
State of Wyoming
Wyoming
$71.7K +$100K +46,861 New
PAS
65
Point72 Asia (Singapore)
Singapore
$69.9K -$5.39K -2,528 -5%
Cambridge Investment Research Advisors
66
Cambridge Investment Research Advisors
Iowa
$64K – – –
OAM
67
Oxford Asset Management
United Kingdom
$63.8K +$89K +41,723 New
EGM
68
Engineers Gate Manager
New York
$61.6K -$114K -53,305 -57%
JFG
69
Jefferies Financial Group
New York
$61.5K -$1.07K -500 -1%
AG
70
Algert Global
California
$61K +$85K +39,850 New
QC
71
Quadrature Capital
United Kingdom
$59.8K +$83.9K +39,331 New
Mariner
72
Mariner
Kansas
$58.1K +$416 +195 +0.5%
CGIM
73
Cannon Global Investment Management
Florida
$57.2K +$79.8K +37,400 New
Verition Fund Management
74
Verition Fund Management
Connecticut
$54.8K +$76.4K +35,805 New
VCIM
75
Velan Capital Investment Management
Georgia
$53.5K +$17.1K +8,000 +30%
1 2
3
4 5

ACRS Hedge Fund Activity: Q1 2025 in Review

109 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2025, worth a combined $144M — down 34% from $217M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ACRS positions and 12 closed out — a net gain of 11 holders — while 39 added to existing stakes and 27 trimmed.

The largest buyer was Millennium Management, adding an estimated $4.64M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $6.99M sold.

  • 109 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2025, up from 98 in Q4 2024.
  • Funds reported $144M of Aclaris Therapeutics stock for Q1 2025, down 34% quarter-over-quarter.
  • 23 funds opened new Aclaris Therapeutics positions in Q1 2025 and 12 closed out, a net change of +11 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2025 was Millennium Management, an estimated $4.64M added.
  • The largest Aclaris Therapeutics seller in Q1 2025 was Janus Henderson Group, an estimated $6.99M sold.

Based on aggregated 13F filings for Q1 2025.